FDA Accepts Biogen ’s New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS

SOD1-ALS is a rare genetic form of ALS that affects approximately 330 people in the U.S.,1 it is progressive, leads to the loss of everyday functions and is uniformly fatal If approved, tofersen would be the first treatment to target a genetic...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news